

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Otsuki, et al.
App. No	: 10/785,446
Filed	: February 23, 2004
For	: METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST
Examiner	: Royds, Leslie A.
Art Unit	: 1614
Conf #	: 1443

RESPONSE TO NOTICE OF NON-COMPLIANT RESPONSE TO RESTRICTION
REQUIREMENT**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication regarding Applicants' Response to Restriction Requirement submitted March, 11, 2008, kindly consider the following remarks. Applicants provisionally elect to prosecute claims to Group II, (Claims 10-13 and 26-34), drawn to methods of treating a cardiovascular disease with an adenosine A₁ receptor antagonist. Applicants also elect heart failure as a species of cardiovascular disease, KW-3902 as a species of AA₁RA, and carvedilol as a species of beta blocker. Claims that read on this species include Claims 10-13 and 26-32 and 34.

A Listing of the Claims begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.